Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure
To elucidate whether or not the improvement of anemia with the resultant hyperviscosity is one of the causes of rHuEPO-derived hypertension, the present study was conducted with 29 hemodialysis patients and 15 predialysis patients. They were kept in the supine position for 60 minutes (min) before th...
Gespeichert in:
| Veröffentlicht in: | Nihon Toseki Igakkai Zasshi 1998/09/28, Vol.31(9), pp.1251-1257 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1257 |
|---|---|
| container_issue | 9 |
| container_start_page | 1251 |
| container_title | Nihon Toseki Igakkai Zasshi |
| container_volume | 31 |
| creator | Nakamura, Shinya Yang, Chao Long Nakayama, Kaori Kayama, Masato Adachi, Koshin Mitsuma, Terunori Asada, Hiroaki Tsutsui, Shuichi Ishiguro, Motoyuki Ohashi, Hiroshige Niwamoto, Youko |
| description | To elucidate whether or not the improvement of anemia with the resultant hyperviscosity is one of the causes of rHuEPO-derived hypertension, the present study was conducted with 29 hemodialysis patients and 15 predialysis patients. They were kept in the supine position for 60 minutes (min) before the study and for 60 min during the study. Measurement of blood pressure was done every 30 min and blood samples were obtained before and after the study. Circulating blood cells (CBC), pressor substances such as plasma catecholamines (NA, A), plasma aldosterone concentrations (PAC), plasma renin activity (PRA) and plasma endothelin-1 (ET-1) were assayed. The amount of rHuEPO (Epoetin-β) given intravenously was 3000 units to dialysis patients and 6000 units to predialysis patients. CBC did not change over the 60 min study in either group. In contrast, blood pressure varied from 142.7/76.5mmHg to 145.1/78.6mmHg at 30 min and rose to 150.9 (p |
| doi_str_mv | 10.4009/jsdt.31.1251 |
| format | Article |
| fullrecord | <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4009_jsdt_31_1251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_jsdt1994_31_9_31_9_1251_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1371-8b945412dc6a74b249e850fd88023d609f27aa99917075bcfcb21b0556c8b83b3</originalsourceid><addsrcrecordid>eNo9kFFLwzAUhYsoOKdv_oA8KtiZNEmbPMqYThhMUMG3kqa3NqNLS5IqBX-8rZO93HsP9zvn4UTRNcELhrG83_kyLChZkISTk2hGhKAxFsnH6XhThmPKODmPLrzfYZxKTvAs-nkNfTmgtkKhBqRV78FPyoFu94WxygZU93tlEbgh1K7tWgPBWHTj1v3qZXsbl-DMF5SoHjpwAaw3rUUj0KlgwAaPvk2okR6t1ugx16oGVco0vYPL6KxSjYer_z2P3h9Xb8t1vNk-PS8fNrEmNCOxKCTjjCSlTlXGioRJEBxXpRA4oWWKZZVkSkkpSYYzXuhKFwkpMOepFoWgBZ1Hd4dc7VrvHVR558xeuSEnOJ-ay6fmckryqbkRXx3wnQ_qE46wcsHoBv5gIiWbDPIwJt_xr2vlcrD0F2ypfJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure</title><source>J-STAGE Free</source><creator>Nakamura, Shinya ; Yang, Chao Long ; Nakayama, Kaori ; Kayama, Masato ; Adachi, Koshin ; Mitsuma, Terunori ; Asada, Hiroaki ; Tsutsui, Shuichi ; Ishiguro, Motoyuki ; Ohashi, Hiroshige ; Niwamoto, Youko</creator><creatorcontrib>Nakamura, Shinya ; Yang, Chao Long ; Nakayama, Kaori ; Kayama, Masato ; Adachi, Koshin ; Mitsuma, Terunori ; Asada, Hiroaki ; Tsutsui, Shuichi ; Ishiguro, Motoyuki ; Ohashi, Hiroshige ; Niwamoto, Youko</creatorcontrib><description><![CDATA[To elucidate whether or not the improvement of anemia with the resultant hyperviscosity is one of the causes of rHuEPO-derived hypertension, the present study was conducted with 29 hemodialysis patients and 15 predialysis patients. They were kept in the supine position for 60 minutes (min) before the study and for 60 min during the study. Measurement of blood pressure was done every 30 min and blood samples were obtained before and after the study. Circulating blood cells (CBC), pressor substances such as plasma catecholamines (NA, A), plasma aldosterone concentrations (PAC), plasma renin activity (PRA) and plasma endothelin-1 (ET-1) were assayed. The amount of rHuEPO (Epoetin-β) given intravenously was 3000 units to dialysis patients and 6000 units to predialysis patients. CBC did not change over the 60 min study in either group. In contrast, blood pressure varied from 142.7/76.5mmHg to 145.1/78.6mmHg at 30 min and rose to 150.9 (p<0.05)/79.5mmHg at 60 min in the dialysis patients. Likewise, blood pressure increased from 139.5/74.8mmHg to 147.5/83.2 (p<0.05) mmHg at 30 min and 154.3/85.1mmHg (p<0.005) at 60 min in the predialysis patients. Mean blood pressure increased significantly at 60 min in predialysis patients (p<0.005). Additionally, ET-1 significantly increased from 15.4±3.5pg/ml to 18.1±4.2pg/ml in dialysis patients (p<0.05) and from 13.7±4.3pg/ml to 16.0±4.7pg/ml in predialysis patients (p<0.05). These elevations may be attributed to the increased generation of ET-1 by rHuEPO. A significant elevation of pressor substances (NA, A, PAC and PRA) was not detected. In conclusion, rHuEPO or ET-1 may be one reason for elevated blood pressure.]]></description><identifier>ISSN: 1340-3451</identifier><identifier>EISSN: 1883-082X</identifier><identifier>DOI: 10.4009/jsdt.31.1251</identifier><language>eng</language><publisher>The Japanese Society for Dialysis Therapy</publisher><subject>chronic renal failure ; dialysis ; endothelin-1 ; hypertension ; recombinant human erythropoietin (rHuEPO)</subject><ispartof>Nihon Toseki Igakkai Zasshi, 1998/09/28, Vol.31(9), pp.1251-1257</ispartof><rights>The Japanese Society for Dialysis Therapy</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,27903,27904</link.rule.ids></links><search><creatorcontrib>Nakamura, Shinya</creatorcontrib><creatorcontrib>Yang, Chao Long</creatorcontrib><creatorcontrib>Nakayama, Kaori</creatorcontrib><creatorcontrib>Kayama, Masato</creatorcontrib><creatorcontrib>Adachi, Koshin</creatorcontrib><creatorcontrib>Mitsuma, Terunori</creatorcontrib><creatorcontrib>Asada, Hiroaki</creatorcontrib><creatorcontrib>Tsutsui, Shuichi</creatorcontrib><creatorcontrib>Ishiguro, Motoyuki</creatorcontrib><creatorcontrib>Ohashi, Hiroshige</creatorcontrib><creatorcontrib>Niwamoto, Youko</creatorcontrib><title>Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure</title><title>Nihon Toseki Igakkai Zasshi</title><addtitle>Nihon Toseki Igakkai Zasshi</addtitle><description><![CDATA[To elucidate whether or not the improvement of anemia with the resultant hyperviscosity is one of the causes of rHuEPO-derived hypertension, the present study was conducted with 29 hemodialysis patients and 15 predialysis patients. They were kept in the supine position for 60 minutes (min) before the study and for 60 min during the study. Measurement of blood pressure was done every 30 min and blood samples were obtained before and after the study. Circulating blood cells (CBC), pressor substances such as plasma catecholamines (NA, A), plasma aldosterone concentrations (PAC), plasma renin activity (PRA) and plasma endothelin-1 (ET-1) were assayed. The amount of rHuEPO (Epoetin-β) given intravenously was 3000 units to dialysis patients and 6000 units to predialysis patients. CBC did not change over the 60 min study in either group. In contrast, blood pressure varied from 142.7/76.5mmHg to 145.1/78.6mmHg at 30 min and rose to 150.9 (p<0.05)/79.5mmHg at 60 min in the dialysis patients. Likewise, blood pressure increased from 139.5/74.8mmHg to 147.5/83.2 (p<0.05) mmHg at 30 min and 154.3/85.1mmHg (p<0.005) at 60 min in the predialysis patients. Mean blood pressure increased significantly at 60 min in predialysis patients (p<0.005). Additionally, ET-1 significantly increased from 15.4±3.5pg/ml to 18.1±4.2pg/ml in dialysis patients (p<0.05) and from 13.7±4.3pg/ml to 16.0±4.7pg/ml in predialysis patients (p<0.05). These elevations may be attributed to the increased generation of ET-1 by rHuEPO. A significant elevation of pressor substances (NA, A, PAC and PRA) was not detected. In conclusion, rHuEPO or ET-1 may be one reason for elevated blood pressure.]]></description><subject>chronic renal failure</subject><subject>dialysis</subject><subject>endothelin-1</subject><subject>hypertension</subject><subject>recombinant human erythropoietin (rHuEPO)</subject><issn>1340-3451</issn><issn>1883-082X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNo9kFFLwzAUhYsoOKdv_oA8KtiZNEmbPMqYThhMUMG3kqa3NqNLS5IqBX-8rZO93HsP9zvn4UTRNcELhrG83_kyLChZkISTk2hGhKAxFsnH6XhThmPKODmPLrzfYZxKTvAs-nkNfTmgtkKhBqRV78FPyoFu94WxygZU93tlEbgh1K7tWgPBWHTj1v3qZXsbl-DMF5SoHjpwAaw3rUUj0KlgwAaPvk2okR6t1ugx16oGVco0vYPL6KxSjYer_z2P3h9Xb8t1vNk-PS8fNrEmNCOxKCTjjCSlTlXGioRJEBxXpRA4oWWKZZVkSkkpSYYzXuhKFwkpMOepFoWgBZ1Hd4dc7VrvHVR558xeuSEnOJ-ay6fmckryqbkRXx3wnQ_qE46wcsHoBv5gIiWbDPIwJt_xr2vlcrD0F2ypfJw</recordid><startdate>19980928</startdate><enddate>19980928</enddate><creator>Nakamura, Shinya</creator><creator>Yang, Chao Long</creator><creator>Nakayama, Kaori</creator><creator>Kayama, Masato</creator><creator>Adachi, Koshin</creator><creator>Mitsuma, Terunori</creator><creator>Asada, Hiroaki</creator><creator>Tsutsui, Shuichi</creator><creator>Ishiguro, Motoyuki</creator><creator>Ohashi, Hiroshige</creator><creator>Niwamoto, Youko</creator><general>The Japanese Society for Dialysis Therapy</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19980928</creationdate><title>Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure</title><author>Nakamura, Shinya ; Yang, Chao Long ; Nakayama, Kaori ; Kayama, Masato ; Adachi, Koshin ; Mitsuma, Terunori ; Asada, Hiroaki ; Tsutsui, Shuichi ; Ishiguro, Motoyuki ; Ohashi, Hiroshige ; Niwamoto, Youko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1371-8b945412dc6a74b249e850fd88023d609f27aa99917075bcfcb21b0556c8b83b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>chronic renal failure</topic><topic>dialysis</topic><topic>endothelin-1</topic><topic>hypertension</topic><topic>recombinant human erythropoietin (rHuEPO)</topic><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Shinya</creatorcontrib><creatorcontrib>Yang, Chao Long</creatorcontrib><creatorcontrib>Nakayama, Kaori</creatorcontrib><creatorcontrib>Kayama, Masato</creatorcontrib><creatorcontrib>Adachi, Koshin</creatorcontrib><creatorcontrib>Mitsuma, Terunori</creatorcontrib><creatorcontrib>Asada, Hiroaki</creatorcontrib><creatorcontrib>Tsutsui, Shuichi</creatorcontrib><creatorcontrib>Ishiguro, Motoyuki</creatorcontrib><creatorcontrib>Ohashi, Hiroshige</creatorcontrib><creatorcontrib>Niwamoto, Youko</creatorcontrib><collection>CrossRef</collection><jtitle>Nihon Toseki Igakkai Zasshi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Shinya</au><au>Yang, Chao Long</au><au>Nakayama, Kaori</au><au>Kayama, Masato</au><au>Adachi, Koshin</au><au>Mitsuma, Terunori</au><au>Asada, Hiroaki</au><au>Tsutsui, Shuichi</au><au>Ishiguro, Motoyuki</au><au>Ohashi, Hiroshige</au><au>Niwamoto, Youko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure</atitle><jtitle>Nihon Toseki Igakkai Zasshi</jtitle><addtitle>Nihon Toseki Igakkai Zasshi</addtitle><date>1998-09-28</date><risdate>1998</risdate><volume>31</volume><issue>9</issue><spage>1251</spage><epage>1257</epage><pages>1251-1257</pages><issn>1340-3451</issn><eissn>1883-082X</eissn><abstract><![CDATA[To elucidate whether or not the improvement of anemia with the resultant hyperviscosity is one of the causes of rHuEPO-derived hypertension, the present study was conducted with 29 hemodialysis patients and 15 predialysis patients. They were kept in the supine position for 60 minutes (min) before the study and for 60 min during the study. Measurement of blood pressure was done every 30 min and blood samples were obtained before and after the study. Circulating blood cells (CBC), pressor substances such as plasma catecholamines (NA, A), plasma aldosterone concentrations (PAC), plasma renin activity (PRA) and plasma endothelin-1 (ET-1) were assayed. The amount of rHuEPO (Epoetin-β) given intravenously was 3000 units to dialysis patients and 6000 units to predialysis patients. CBC did not change over the 60 min study in either group. In contrast, blood pressure varied from 142.7/76.5mmHg to 145.1/78.6mmHg at 30 min and rose to 150.9 (p<0.05)/79.5mmHg at 60 min in the dialysis patients. Likewise, blood pressure increased from 139.5/74.8mmHg to 147.5/83.2 (p<0.05) mmHg at 30 min and 154.3/85.1mmHg (p<0.005) at 60 min in the predialysis patients. Mean blood pressure increased significantly at 60 min in predialysis patients (p<0.005). Additionally, ET-1 significantly increased from 15.4±3.5pg/ml to 18.1±4.2pg/ml in dialysis patients (p<0.05) and from 13.7±4.3pg/ml to 16.0±4.7pg/ml in predialysis patients (p<0.05). These elevations may be attributed to the increased generation of ET-1 by rHuEPO. A significant elevation of pressor substances (NA, A, PAC and PRA) was not detected. In conclusion, rHuEPO or ET-1 may be one reason for elevated blood pressure.]]></abstract><pub>The Japanese Society for Dialysis Therapy</pub><doi>10.4009/jsdt.31.1251</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-3451 |
| ispartof | Nihon Toseki Igakkai Zasshi, 1998/09/28, Vol.31(9), pp.1251-1257 |
| issn | 1340-3451 1883-082X |
| language | eng |
| recordid | cdi_crossref_primary_10_4009_jsdt_31_1251 |
| source | J-STAGE Free |
| subjects | chronic renal failure dialysis endothelin-1 hypertension recombinant human erythropoietin (rHuEPO) |
| title | Study of the causes of recombinant human erythropoietin (rHuEPO)-derived hypertension in patients with chronic renal failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A57%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Study%20of%20the%20causes%20of%20recombinant%20human%20erythropoietin%20(rHuEPO)-derived%20hypertension%20in%20patients%20with%20chronic%20renal%20failure&rft.jtitle=Nihon%20Toseki%20Igakkai%20Zasshi&rft.au=Nakamura,%20Shinya&rft.date=1998-09-28&rft.volume=31&rft.issue=9&rft.spage=1251&rft.epage=1257&rft.pages=1251-1257&rft.issn=1340-3451&rft.eissn=1883-082X&rft_id=info:doi/10.4009/jsdt.31.1251&rft_dat=%3Cjstage_cross%3Earticle_jsdt1994_31_9_31_9_1251_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |